Nicholas Piramal India Limited (NPIL)
Nicholas Piramal India Limited (NPIL) is India's second largest Pharmaceutical and Healthcare company. NPIL is a leader in the Cardio-vascular segment, and has a strong presence in Antibiotics and Respiratory segments, Pain management, Neuro-psychiatry and Anti-Diabetics segments. In 2005-06 its revenues stood at Rs 14.1 billion and PAT at Rs 1.7 billion.
NPIL which has been in the pharma business for just 15 years, has grown through an aggressive strategy of successfully managed acquisitions, mergers and alliances. NPIL's core strengths are its 2700-strong field force; successful brand building - today 16 of its brands are among the top 300 in the Indian pharma industry; state-of-the-art manufacturing plants - NPIL's Hyderabad plant is the only one in India to have USFDA approval for the entire facility and its unique ability to successfully manage partnerships in the business which is respected globally.NPIL has also emerged as one of the leading custom manufacturing organizations in the world. NPIL also has major investments in R&D within Inia and abroad. which focus on formulations development, new chemical entity research, clinical research.
NPIL is part of the Rs. 2500 crore (US $ 500 million) Piramal Enterprises (PEL), one of India's largest diversified business houses. The Group is headed by Mr. Ajay Piramal, who is also the Chairman of NPIL.